ZT002 / Beijing QL Biopharma - LARVOL DELTA

A Phase II Study of ZT002 Injection With Subjects With Overweight or Obesity (clinicaltrials.gov) - P2 | N=300 | Active, not recruiting | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P2 trial • Genetic Disorders • Obesity

ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1c study (EASD 2024) - "This MAD trial demonstrated biweekly treatment with ZT002 induced clinically meaningful weight loss and cardiometabolic improvements with favorable tolerability and safety profiles. Further clinical evaluation of ZT002, including monthly subcutaneous administration for overweight/obesity, is ongoing."

Clinical • Metabolic Disorders • Obesity

A SAD Study of ZT002 Injection in Healthy Participants (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of ZT002 Injection in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=28 | Enrolling by invitation | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P1 trial • Genetic Disorders • Obesity

A Study of ZT002 in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: QL Biopharmaceutical Australia Pty Ltd | Not yet recruiting ➔ Recruiting | N=32 ➔ 56 | Trial completion date: Aug 2023 ➔ Apr 2024 | Trial primary completion date: Feb 2023 ➔ Dec 2023

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of ZT002 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: QL Biopharmaceutical Australia Pty Ltd

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus